Coeptis Therapeutics Hldgs I
13F holders, Q3 2025 (September 30)10holders +1
4new positions
3sold out
1famous investor
$17.46avg. 13F price*
At the end of Q3 2025, 10 institutions reported holding Coeptis Therapeutics Hldgs I in their 13F filings, up 1 from Q2 2025. 4 opened new positions and 3 sold out. The largest holders were Vanguard Group Inc. ($885K), Geode Capital Management, LLC ($653K) and State Street Corp. ($347K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Coeptis Therapeutics Hldgs I
- CUSIP
- 19207A207
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $681K |
| Exits | 3 | $3K |
All 13F filers, Q2 2025 → Q3 2025: 80,783 shares bought and 45,075 shares sold, net +35,708 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Vanguard Group Inc. | 0.00% | Add +84.1% | 50,675 | $885K |
| Geode Capital Management, LLC | 0.00% | Add +84.3% | 37,376 | $653K |
| State Street Corp. | 0.00% | New | 19,868 | $347K |
| Renaissance Technologies | 0.00% | New | 18,500 | $323K |
| Yorkville Advisors Global, LP | 0.05% | Reduce -84.8% | 8,000 | $140K |
| Steward Partners Investment Advisory, LLC | 0.00% | Add +150.0% | 2,500 | $44K |
| PNC Financial Services Group, Inc. | 0.00% | New | 463 | $8K |
| Morgan Stanley | 0.00% | New | 200 | $3K |
| Bank of America Corp. | 0.00% | Add +40.0% | 35 | $611 |
| Barclays PLC | 0.00% | No change | 3 | $52 |
"% of holder's portfolio" is COEPTIS THERAPEUTICS HLDGS I's weight in each manager's 13F, not the share of Coeptis Therapeutics Hldgs I the manager owns.